BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 21943799)

  • 1. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
    Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
    Lopez D
    Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PCSK9 for the treatment of hypercholesterolemia.
    Hedrick JA
    Curr Opin Investig Drugs; 2009 Sep; 10(9):938-46. PubMed ID: 19705336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P; Just IA; Kaschina E
    Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9: an emerging target for treatment of hypercholesterolemia.
    Duff CJ; Hooper NM
    Expert Opin Ther Targets; 2011 Feb; 15(2):157-68. PubMed ID: 21204732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.
    Nassoury N; Blasiole DA; Tebon Oler A; Benjannet S; Hamelin J; Poupon V; McPherson PS; Attie AD; Prat A; Seidah NG
    Traffic; 2007 Jun; 8(6):718-32. PubMed ID: 17461796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9: a key modulator of cardiovascular health.
    Seidah NG; Awan Z; Chrétien M; Mbikay M
    Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PCSK9 therapies for the treatment of hypercholesterolemia.
    Hooper AJ; Burnett JR
    Expert Opin Biol Ther; 2013 Mar; 13(3):429-35. PubMed ID: 23240807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
    Farnier M
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):145-52. PubMed ID: 21619378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of PCSK9 function.
    Lambert G; Charlton F; Rye KA; Piper DE
    Atherosclerosis; 2009 Mar; 203(1):1-7. PubMed ID: 18649882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia.
    Maxwell KN; Breslow JL
    Curr Opin Lipidol; 2005 Apr; 16(2):167-72. PubMed ID: 15767856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 gene mutations and low-density lipoprotein cholesterol.
    Wu NQ; Li JJ
    Clin Chim Acta; 2014 Apr; 431():148-53. PubMed ID: 24518357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A; Demir K; Altunkeser BB
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.